| Drug Type Small molecule drug | 
| Synonyms Sabarubicin, BMS 195615, BMS-195615 + [1] | 
| Target | 
| Action inhibitors | 
| Mechanism Top II inhibitors(Topoisomerase II inhibitors) | 
| Therapeutic Areas | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| RegulationSpecial Review Project (China) | 
| Molecular FormulaC32H38ClNO13 | 
| InChIKeyBSRQHWFOFMAZRL-BODGVHBXSA-N | 
| CAS Registry169317-77-5 | 
| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | Sabarubicin Hydrochloride | - | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Castration-Resistant Prostatic Cancer | Phase 2 | Belgium  | 01 Aug 2001 | |
| Castration-Resistant Prostatic Cancer | Phase 2 | France  | 01 Aug 2001 | |
| Castration-Resistant Prostatic Cancer | Phase 2 | Germany  | 01 Aug 2001 | |
| Castration-Resistant Prostatic Cancer | Phase 2 | Israel  | 01 Aug 2001 | |
| Castration-Resistant Prostatic Cancer | Phase 2 | Spain  | 01 Aug 2001 | |
| Castration-Resistant Prostatic Cancer | Phase 2 | Switzerland  | 01 Aug 2001 | |
| Recurrent Lung Small Cell Carcinoma | Phase 1 | China  | 30 Dec 2014 | |
| Recurrent Lung Small Cell Carcinoma | Phase 1 | China  | 30 Dec 2014 | |
| Refractory Small Cell Lung Carcinoma | Phase 1 | China  | 30 Dec 2014 | |
| Refractory Small Cell Lung Carcinoma | Phase 1 | China  | 30 Dec 2014 | 
| Phase 1/2 | Extensive stage Small Cell Lung Cancer First line | - | jhudmiroom(fxmloqsofx) = oskhtonqcn excctqpnrl (vijdzeuqam ) View more | - | 20 May 2010 | ||
| Phase 2 | 26 | ezoxeopmba(adoufrspqn) = svqopnxcuv tkggbdlpde (vkumlscwpx, 22.43 - 57.46) View more | - | 20 May 2008 | |||
| Phase 2 | - | Sabarubicin (MEN-10755) | kcmtbnywic(awinimcdut) = exkvohvawb orfgnzdxqh (lhwyxxkhcr ) View more | - | 01 Jan 2006 | 





